Am J Transplant, Volume 17, Suppl 3 Archives - Page 181 of 181 - ATC Abstracts

2017 American Transplant Congress
Chronic Antibody Mediated Rejection (cABMR) in ABO-Incompatible and ABO-Compatible Kidney Transplants: A Single US Center Experience.
S. Sethi, A. Vo, E. Huang, L. Varanasi, J. Choi, A. Peng, R. Najjar, S. Jordan.
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
Introduction:Similar patient and graft outcomes have been previously reported for ABO compatible (ABOc) and ABO incompatible (ABOi) kidney transplants. However, data are limited on the…
2017 American Transplant Congress
Poor Prediction of Rejection and Kidney Survival by Donor-Specific-Antibodies Characterization.
L. Couzi,^1,2,3 M. Courant,¹ J. Visentin,^1,2,3 V. Dubois,⁴ S. Lepreux,^1,2 G. Guidicelli,¹ O. Thaunat,^5,6 P. Merville,^1,2,3 J.-L. Taupin.⁷
¹CHU de Bordeaux, Bordeaux, France; ²Université de Bordeaux, Bordeaux, France; ³UMR CNRS 5164 Immunoconcept, Bordeaux, France; ⁴Etablissement Français du Sang, Lyon, France; ⁵INSERM U1111, Lyon, France; ⁶CHU de Lyon, Lyon, France; ⁷Laboratoire d'Immunologie et Histocompatibilité, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
Kidney transplant recipients with DSA have a greater likelihood of developing antibody-mediated rejection (ABMR) and kidney allograft loss. The aim of this study was to…
2017 American Transplant Congress
Liver Mesenchymal Stem Cells Inhibit T Cell Alloresponses.
T. Taner, M. Gustafson, M. Hansen, A. Dietz, M. Stegall.
Mayo Clinic, Rochester, MN
Clinical and histologic evidence suggest that the liver allograft induces alloimmune hyporesponsiveness in the recipient. Mesenchymal stem cells (MSC) are multipotent non-hematopoietic stromal cells with…
2017 American Transplant Congress
Prognostic Tools to Choose Candidates for Successful Desensitization.
D. Pinelli,¹ A. Zachary,² J. Friedewald,¹ M. Leffell,² D. Lucas,² R. Montgomery,² A. Tambur.¹
¹Northwestern University, Chicago, IL; ²Johns Hopkins, Baltimore, MD
Antibodies to donor HLA antigens are a barrier to solid organ transplantation. Strategies to desensitize patients have improved, but the ability to predict response to…
2017 American Transplant Congress
Hepatic Artery and Biliary Complications in Liver Transplant Recipients with Radioembolization Bridging Treatment for Hepatocellular Carcinoma.
S. Radunz,¹ J. Treckmann,¹ F. Saner,¹ S. Müller,² J. Theysohn,³ A. Paul,¹ T. Benkö.¹
¹General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany; ²Nuclear Medicine, University Hospital Essen, Essen, Germany; ³Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
Locoregional treatments are commonly applied in hepatocellular carcinoma (HCC) patients as a bridge to liver transplantation to prevent tumor progression during waiting time. We hypothesized…
2017 American Transplant Congress
Outcomes Following Transplantation for Hepatocellular Carcinoma.
P. Tabrizian, K. Nakazawa, J. Prigoff, M. Schwartz, S. Florman.
Transplant, Recanati/Miller Transplantation Institute, New York, Ny
Objectives: To examine the prognostic features and outcomes of patients undergoing transplantation for hepatocellular carcinoma (HCC).Methods: A single-institution retrospective chart review was performed on all…